CA2759836A1 - Humanized axl antibodies - Google Patents

Humanized axl antibodies Download PDF

Info

Publication number
CA2759836A1
CA2759836A1 CA2759836A CA2759836A CA2759836A1 CA 2759836 A1 CA2759836 A1 CA 2759836A1 CA 2759836 A CA2759836 A CA 2759836A CA 2759836 A CA2759836 A CA 2759836A CA 2759836 A1 CA2759836 A1 CA 2759836A1
Authority
CA
Canada
Prior art keywords
seq
axl
serine
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2759836A
Other languages
English (en)
French (fr)
Inventor
Peter Wirtz
Jens Ruhe
Takeshi Takizawa
Tomoko Takayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Europe GmbH
Original Assignee
U3 Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09006355A external-priority patent/EP2270053A1/en
Application filed by U3 Pharma GmbH filed Critical U3 Pharma GmbH
Publication of CA2759836A1 publication Critical patent/CA2759836A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2759836A 2009-05-11 2010-05-11 Humanized axl antibodies Abandoned CA2759836A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09006355.3 2009-05-11
EP09006355A EP2270053A1 (en) 2009-05-11 2009-05-11 Humanized AXL antibodies
EP09006474.2 2009-05-13
EP09006474 2009-05-13
PCT/EP2010/056487 WO2010130751A1 (en) 2009-05-11 2010-05-11 Humanized axl antibodies

Publications (1)

Publication Number Publication Date
CA2759836A1 true CA2759836A1 (en) 2010-11-18

Family

ID=42272537

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2759836A Abandoned CA2759836A1 (en) 2009-05-11 2010-05-11 Humanized axl antibodies

Country Status (15)

Country Link
US (2) US8841424B2 (enExample)
EP (1) EP2430050A1 (enExample)
JP (2) JP5909442B2 (enExample)
KR (1) KR20120035145A (enExample)
CN (1) CN102421802B (enExample)
AR (1) AR076564A1 (enExample)
AU (1) AU2010247464B2 (enExample)
BR (1) BRPI1013428A2 (enExample)
CA (1) CA2759836A1 (enExample)
IL (1) IL216147A (enExample)
MX (1) MX2011011825A (enExample)
RU (2) RU2571224C2 (enExample)
TW (2) TWI526223B (enExample)
WO (1) WO2010130751A1 (enExample)
ZA (1) ZA201107529B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076564A1 (es) * 2009-05-11 2011-06-22 U3 Pharma Gmbh Anticuerpos humanizados de axl(receptor de tirosina quinasa)
EP2483289B2 (en) 2009-10-02 2025-03-26 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
US9562252B2 (en) 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
WO2012175691A1 (en) * 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
AU2012273955A1 (en) * 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
KR102167228B1 (ko) * 2012-11-05 2020-10-19 피에르 파브르 메디카먼트 새로운 항원 결합 단백질들 및 암의 치료를 위한 어드레싱 산물로서 그들의 용도
US9822347B2 (en) * 2012-12-14 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
EP3229836B1 (en) * 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016097370A2 (en) 2014-12-18 2016-06-23 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
GB201506411D0 (en) * 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
ES3063952T3 (en) * 2015-05-18 2026-04-21 Agensys Inc Antibodies that bind to axl proteins
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
CA2991805A1 (en) 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
CN110922481A (zh) 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
EP4656204A3 (en) * 2016-04-15 2026-06-03 BioAtla, Inc. Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109160941B (zh) * 2018-09-29 2020-09-04 未名生物医药有限公司 蛋白序列17e11及其用途
RU2678569C1 (ru) * 2018-10-31 2019-01-30 Гордейчук Владимир Евгеньевич Способ подавления метастазирования опухолей
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN110982791A (zh) * 2019-12-26 2020-04-10 百泰生物药业有限公司 一种分泌axl抗体的杂交瘤细胞的制备筛选方法
CN115052663B (zh) 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
US11807688B2 (en) * 2020-02-28 2023-11-07 Les Laboratoires Servier Anti-AXL antibodies and compositions
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
WO2021204713A1 (en) 2020-04-08 2021-10-14 Bergenbio Asa Axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
WO2022164288A1 (ko) 2021-01-29 2022-08-04 한국과학기술원 비염증성 식세포작용 유도 활성을 갖는 융합분자
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
CN115927243A (zh) * 2022-09-13 2023-04-07 中山大学 一种akt1蛋白的抑制性磷酸化位点及其应用
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
DE3900534A1 (de) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO1997034636A1 (en) * 1996-03-20 1997-09-25 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
EP1190061A1 (en) 1999-06-07 2002-03-27 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
EP1891110A2 (en) 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
EP2170395A1 (en) 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
CA2703519C (en) * 2007-11-09 2017-04-18 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
BRPI0820073A2 (pt) * 2007-11-12 2015-06-23 U3 Pharma Gmbh Anticorpos anti-axl
AR076564A1 (es) * 2009-05-11 2011-06-22 U3 Pharma Gmbh Anticuerpos humanizados de axl(receptor de tirosina quinasa)

Also Published As

Publication number Publication date
US20120117670A1 (en) 2012-05-10
BRPI1013428A2 (pt) 2019-07-02
CN102421802B (zh) 2014-08-20
TW201105348A (en) 2011-02-16
KR20120035145A (ko) 2012-04-13
MX2011011825A (es) 2011-12-06
ZA201107529B (en) 2012-06-27
AU2010247464B2 (en) 2014-09-11
US20150037323A1 (en) 2015-02-05
IL216147A (en) 2016-04-21
CN102421802A (zh) 2012-04-18
TW201509431A (zh) 2015-03-16
RU2011150183A (ru) 2013-06-20
EP2430050A1 (en) 2012-03-21
US8841424B2 (en) 2014-09-23
TWI526223B (zh) 2016-03-21
WO2010130751A1 (en) 2010-11-18
JP2016011306A (ja) 2016-01-21
RU2015147287A (ru) 2017-05-12
IL216147A0 (en) 2012-01-31
RU2571224C2 (ru) 2015-12-20
AU2010247464A1 (en) 2011-11-10
AR076564A1 (es) 2011-06-22
JP2012526530A (ja) 2012-11-01
JP5909442B2 (ja) 2016-04-26

Similar Documents

Publication Publication Date Title
AU2010247464B2 (en) Humanized AXL antibodies
JP7520848B2 (ja) 癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
AU2008323206B2 (en) AXL antibodies
KR102589136B1 (ko) 항-b7-h3 항체 및 그 용도
KR101671039B1 (ko) 항 ｃｘｃｒ4 항체 및 그들의 암의 치료를 위한 용도
TW202016135A (zh) Ｐｓｍａ結合劑及其用途
KR102405278B1 (ko) Alk7 결합 단백질 및 이들의 용도
CA3027417A1 (en) Anti-human trop-2 antibody having an antitumor activity in vivo
KR20210107731A (ko) Pmel17에 대한 항체 및 이의 접합체
EP2270053A1 (en) Humanized AXL antibodies
CA3249959A1 (en) ANTI-CXCL1 HUMAN ANTIBODY
US20150152193A1 (en) Axl antibodies
JP2025516434A (ja) 抗ｃｄ７３抗体およびその使用
HK40003020A (en) Alk7 binding proteins and uses thereof
HK1147275B (en) Axl antibodies
HK1185622B (zh) Axl抗体
HK1178910B (en) Humanized anti cxcr4 antibodies for the treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150129

FZDE Discontinued

Effective date: 20180511